Drug intelligence / Profile preview

siRNA-CHK

Development stage: Preclinical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

siRNA-CHK is a small interfering RNA (siRNA) designed to transiently down-regulate Choline kinase (Chk), an enzyme responsible for converting choline to phosphocholine. Chk is often elevated in cancer cells, making it a potential therapeutic target. Studies have shown that siRNA-CHK can decrease phosphocholine levels and inhibit the proliferation of breast cancer cells, particularly when combined with the anticancer drug 5-fluorouracil (5-FU). This approach aims to enhance the effect of anticancer drugs in malignant cells while having minimal impact on non-malignant cells.

Targets

CHKA (Choline kinase)

Beyond the preview

Go deeper on siRNA-CHK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on siRNA-CHK.

Explore the full profile